Caplin One Labs Limited, a wholly owned subsidiary of Caplin Point Laboratories Limited, has announced the completion of its state-of-the-art Oncology facility at Kakkalur, near Chennai, and immediate commencement of operations. The total investment commitment for this facility is Rs. 150 crores, funded entirely from internal accruals. To start with, the unit will focus on manufacturing a range of Oral Solid Dosage Oncology products, with the Injectable division to commence operations in the next few months. The company plans to expand the portfolio to over 50 oncology products progressively.

The facility will manufacture tablets (both coated & uncoated), capsules, and injections, catering to the growing demand for high-quality pharmaceuticals in the oncology segment. Initially, these oncology products will be targeted at Latin American countries, leveraging Caplin Group's established presence in these markets. In the medium term, Caplin One Labs Limited aims to launch these oncology products in regulated markets such as the US, EU, Mexico, and others.

The facility's compliance with US FDA standards from the outset is expected to streamline the approval process, ensuring swift market entry and availability of these critical treatments to patients worldwide. Caplin Group remains dedicated to advancing healthcare solutions, improving patient outcomes, and making a positive impact on communities globally.

Commenting on the achievement, C.C. Paarthipan, Chairman said: "We are pleased to announce the commencement of operations at our Oncology facility located in Kakkalur. We are committed to delivering superior pharmaceutical products and increasing our market footprint. Caplin has started offering a comprehensive array of oncology solutions to address unmet medical needs, reflecting its dedication to healthcare innovation. Our focus on innovation and technology along with regulatory compliance, well positions us for the long-term success.”